Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
LII enters its October 22 print with the story having shifted subtly since Tuesday: short interest has edged back slightly from its 30-day high, the stock has recovered to $357.73, and the index-rebalance overhang has come into sharper focus as the rank date for MSCI's November review lands today.
The MSCI angle is now the most structurally distinct feature of this setup. ORTEX forecasts a 98% probability that LII leaves the MSCI USA, MSCI World, MSCI Kokusai, and MSCI North America indices at the November 2026 Quarterly Review, while simultaneously joining the MSCI USA Small and MSCI World Small. The combined selling flow from the large-cap deletions is forecast at up to $672M across indices, equivalent to 3.6 days of normal trading volume for the MSCI World deletion alone. The announcement is expected November 11, with the trade date November 30. The stock would need to close above $436.59 to flip the index rule, currently sitting 21.8% above the current price. That gap makes a reprieve at the November review effectively impossible at current levels.
Short interest has eased fractionally from the peak reported earlier in the week. Shorts now account for 7.6% of free float, down just 0.4% on the day but still up 19% over the week and 54% over the month. The borrow market remains untroubled by the increase: cost to borrow is 0.54%, only marginally above its recent range, and availability is ample at 418%, meaning roughly four shares are available to borrow for every one already lent out. Options positioning is slightly below the 20-day average put/call ratio of 1.22, with the current reading at 1.14, about two-thirds of a standard deviation below that mean. Neither the lending market nor options suggests aggressive short-side pressure building beyond what the index mechanics alone explain.
The analyst picture has deteriorated further since the Goldman downgrade on October 14. Morgan Stanley's Betsy Graseck cut her target to $350 from $375 the following morning, keeping an Underweight rating, while Mizuho's Brett Linzey trimmed to $395 from $450. The mean target now stands at $449, implying around 26% upside from $357.73, but the direction of travel across the Street is uniformly downward. The last genuinely bullish action visible in the data is Oppenheimer maintaining Outperform, though even that firm cut its target to $548 from $575. The EPS momentum factor scores reflect the same trend: the 30-day reading ranks in the 15th percentile, and the 90-day in the 19th, signalling consensus estimate cuts have been persistent rather than one-off. The one counterweight is a forward EPS growth score in the 70th percentile, meaning the Street still sees earnings recovering from here, just not quickly.
The activist dimension remains on the register. John Norris III, who filed a Schedule 13D/A in June 2025 disclosing a 9.8% stake (up from 9.2%), remains the most prominent holder on the 13D register, a flag that someone with activist-grade ownership has a material interest in the outcome. As the disclosure note requires: stakes are as last disclosed and a holder can fall below 5% without a further filing.
Wednesday's print will test whether management can offer a recovery timeline credible enough to arrest the rate of estimate cuts, against a mechanical index backdrop that guarantees forced selling regardless of what the numbers say.
See the live data behind this article on ORTEX.
Open LII on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
